Based on the Disc Medicine Inc. stock forecast from 10 analysts, the average analyst target price for Disc Medicine Inc. is USD 84.95 over the next 12 months. Disc Medicine Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Disc Medicine Inc. is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Disc Medicine Inc.’s stock price was USD 63.50. Disc Medicine Inc.’s stock price has changed by -3.69% over the past week, +10.72% over the past month and +8.49% over the last year.
No recent analyst target price found for Disc Medicine Inc.
No recent average analyst rating found for Disc Medicine Inc.
Company Overview Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. Read Less
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembl...Read More
Frequently Asked Questions About Disc Medicine Inc. (IRON) Stock
Based on ratings from 10 analysts Disc Medicine Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 19 buy, sell and hold ratings.
Unfortunately we do not have enough data on IRON's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for IRON is USD 84.95 over the next 12 months. The maximum analyst target price is USD 118 while the minimum anlayst target price is USD 57.
IRON stock's Price/Earning ratio is 4.93.
Our analysis grades IRON stock's Price / Earning ratio at F. This means that IRON stock's Price/Earning ratio is above 48% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this IRON may be fairly valued for its sector
The last closing price of IRON's stock was USD 63.50.
The most recent market capitalization for IRON is USD 2.01B.
Based on targets from 10 analysts, the average taret price for IRON is projected at USD 84.95 over the next 12 months.
This means that IRON's stock price may go up by +33.78% over the next 12 months.
We can't find any ETFs which contains Disc Medicine Inc.'s stock.
As per our most recent records Disc Medicine Inc. has 82 Employees.
Disc Medicine Inc.'s registered address is 321 Arsenal Street, Watertown, MA, United States, 02472.
You can get more information about it from Disc Medicine Inc.'s website at https://www.discmedicine.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Disc Medicine Inc. (IRON) Stock
Based on ratings from 10 analysts Disc Medicine Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 19 buy, sell and hold ratings.
Unfortunately we do not have enough data on IRON's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for IRON is USD 84.95 over the next 12 months. The maximum analyst target price is USD 118 while the minimum anlayst target price is USD 57.
IRON stock's Price/Earning ratio is 4.93.
Our analysis grades IRON stock's Price / Earning ratio at F. This means that IRON stock's Price/Earning ratio is above 48% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this IRON may be fairly valued for its sector
The last closing price of IRON's stock was USD 63.50.
The most recent market capitalization for IRON is USD 2.01B.
Based on targets from 10 analysts, the average taret price for IRON is projected at USD 84.95 over the next 12 months.
This means that IRON's stock price may go up by +33.78% over the next 12 months.
We can't find any ETFs which contains Disc Medicine Inc.'s stock.
As per our most recent records Disc Medicine Inc. has 82 Employees.
Disc Medicine Inc.'s registered address is 321 Arsenal Street, Watertown, MA, United States, 02472.
You can get more information about it from Disc Medicine Inc.'s website at https://www.discmedicine.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IRON !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
